EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Functionality of Anti‐ GPC3 CAR ‐T Cells Against Hepatocellular Carcinoma Through Locoregional Administration

Jue Wang, Jiale Qiu, Kin Ching Tsang, Zezhuo Su, Chenzi Zhang, Jun Tang, Yaofeng Wang, Chenqing Zhang, Chi-Kong Li, Guangjin Pan, Bo Feng

Liver International · 2025-12 · 45 (12)

DOI: 10.1111/liv.70450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 21.11.2025. Verfasst von Jue Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Medicine; CUHK-GIBH CAS Joint Research Laboratory on Stem Cell and Regenerative Medicine, The Chinese Unive…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Adoptive, Glypicans. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims The prognosis for patients with hepatocellular carcinoma (HCC) remains suboptimal, despite the rapid advancement of anti‐cancer immunotherapy. Chimeric antigen receptor (CAR) T cell therapy targeting glypican‐3 (GPC3) has been developed for HCC; however, clinical trials have demonstrated heterogeneous responses among patients and limited CAR‐T cell infiltration. Locoregional administration has emerged as a promising strategy for CAR‐T therapy against solid tumours, yet its potential for HCC treatment has not been thoroughly explored.

Methods

In this study, we constructed anti‐GPC3 CAR‐T cells and examined their therapeutic efficacy through locoregional and systemic administration using multiple HCC xenograft mouse models.

Results

Comparison of CAR‐T cell injections via portal vein and tail vein in mice with orthotopic HepG2 tumours demonstrated significantly enhanced tumour growth inhibition with locoregional CAR‐T therapy. Consistently, tumour infiltration of CAR‐T cells was significantly enhanced by portal vein injection and correlated with increased cytotoxicity, enhanced chemotaxis and reduced exhaustion of the tumour‐infiltrating CAR‐T cells compared to the tail vein injection group. Treatment with escalating CAR‐T cell dosages resulted in further improved functionality of CAR‐T cells and treatment efficacy, alongside improved liver function. Furthermore, portal vein injection exhibited superior tumour inhibition compared to tail vein injection in a metastatic model concurrently bearing orthotopic and extrahepatic tumour lesions.

Conclusion

Collectively, our study demonstrates that locoregional CAR‐T therapy through the portal vein is associated with increased CAR‐T cell infiltration and improved therapeutic efficacy, offering promise for the treatment of both early‐ and late‐stage patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmunotherapy, AdoptiveGlypicansReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansMiceXenograft Model Antitumor AssaysHep G2 CellsPortal Vein

Stichwörter der Autor:innen

CAR‐T therapyGPC3hepatocellular carcinoma (HCC)locoregional therapy

Substanzen

GlypicansReceptors, Chimeric AntigenGPC3 protein, human

Autor:innen und Institutionen

  • School of Biomedical Sciences, Faculty of Medicine; CUHK-GIBH CAS Joint Research Laboratory on Stem Cell and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Orthopaedics and Traumatology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, China.
  • Department of Paediatrics, Hong Kong Children's Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

Zitieren

APA

Wang, J., Qiu, J., Tsang, K. C., Su, Z., Zhang, C., Tang, J., Wang, Y., Zhang, C., Li, C. K., Pan, G., & Feng, B. (2025). Enhanced Functionality of Anti‐ GPC3 CAR ‐T Cells Against Hepatocellular Carcinoma Through Locoregional Administration. Liver International, 45(12). https://doi.org/10.1111/liv.70450

Vancouver

Wang J, Qiu J, Tsang KC, Su Z, Zhang C, Tang J, et al. Enhanced Functionality of Anti‐ GPC3 CAR ‐T Cells Against Hepatocellular Carcinoma Through Locoregional Administration. Liver International. 2025;45(12). doi:10.1111/liv.70450

BibTeX
@article{Wang2025,
  author = {Wang, Jue and Qiu, Jiale and Tsang, Kin Ching and Su, Zezhuo and Zhang, Chenzi and Tang, Jun and Wang, Yaofeng and Zhang, Chenqing and Li, Chi-Kong and Pan, Guangjin and Feng, Bo},
  title = {Enhanced Functionality of Anti‐ GPC3 CAR ‐T Cells Against Hepatocellular Carcinoma Through Locoregional Administration},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {12},
  doi = {10.1111/liv.70450}
}
Kostenlos starten →